1. Scrip
  2. >>New Products

Bristol’s Opdivo Joins Keytruda, Imfinzi In Perioperative NSCLC Treatment Space

 
• By Joseph Haas

PD-1 inhibitor Opdivo has obtained US FDA approval for pre- and post-surgical treatment in operable non-small cell lung cancer, but Merck and AstraZeneca got there first.

Bristol Myers Squibb office building in Brisbane, CA
BMS's Opdivo gets approval for perioperative therapy in resectable NSCLC • Source: Shutterstock

Bristol Myers Squibb Company has racked up another indication for its anti-PD-1 blockbuster Opdivo (nivolumab), joining Merck & Co., Inc.’s PD-1 inhibitor, Keytruda (pembrolizumab), and AstraZeneca PLC’s PD-L1 inhibitor, Imfinzi (durvalumab), with an approval for perioperative combination therapy in resectable non-small cell lung cancer on 4 October.

Key Takeaways

  • BMS gets approval for Opdivo in perioperative resectable non-small cell lung cancer, joining Merck’s Keytruda and AstraZeneca’s Imfinzi in that setting.

  • Bristol noted that Opdivo now is the only PD-1 inhibitor approved for perioperative and adjuvant-only therapy in resectable NSCLC

BMS obtained US Food and Drug Administration approval of Opdivo for presurgical treatment with platinum-doublet chemotherapy and post-surgical monotherapy in adults with operable NSCLC with no known epidermal growth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’